Mehta, Divya
de Boer, Irene
Sutherland, Heidi G.
Pijpers, Judith A.
Bron, Charlene
Bainomugisa, Charlotte
Haupt, Larisa M.
van den Maagdenberg, Arn M. J. M.
Griffiths, Lyn R.
Nyholt, Dale R.
Terwindt, Gisela M.
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (VIDI 91711319, VIDI 91711319, VIDI 91711319, VIDI 91711319)
Article History
Received: 31 May 2023
Accepted: 16 November 2023
First Online: 12 December 2023
Declarations
:
: The study was performed in accordance with the declaration of Helsinki Ethical Principles and approved by the local and national ethics committees. All patients provided written informed consent. Our cohort was collected at the Leiden University Medical Centre as part of the CHARM study (trial register identifier: NTR3440), a randomised clinical trial aimed at assessing whether add-on therapy with botox enhanced the efficacy of acute withdrawal in chronic migraine patients [CitationRef removed].
: Not applicable.
: D. Mehta reports no competing interests. I. de Boer reports grants from Dutch Heart Foundation and the International Retinal Research Foundation (IRRF). H.G. Sutherland, J.A. Pijpers, C. Bron, C. Bainomugisa and L.M. Haupt report no competing interests. L.R. Griffiths reports migraine research funding from the Australian National Health and Medical Research Council (NHMRC-APP1122387), US Migraine Research Foundation, US Dept of Defence and Teva. A.M.J.M. van den Maagdenberg reports grants or consultancy support of Schedule 1 Therapeutics, Praxis Precision Medicine and AbbVie and independent support from Dutch Research Council (NWO and ZonMW) and the European Community. D.R. Nyholt reports migraine research funding unrelated to this study from the Australian National Health and Medical Research Council, US Migraine Research Foundation, US Department of Defence and Teva. G.M. Terwindt reports grants or consultancy support from Novartis, Lilly, Teva, Allergan, Lundbeck and independent support from Dutch Research Council (NWO and ZonMW), European Community, Dutch Heart Foundation, Dutch Brain Foundation, IRRF, and Dioraphte.